With Shrinking Market Share, GSK Sells Augmentin, Amoxil U.S. Rights To Dr. Reddy's, Along With Tennessee Manufacturing Site
This article was originally published in PharmAsia News
MUMBAI - Acting on the strategy of hiving off late-stage brands and non-core assets, GlaxoSmithKline Pharma has sold its once marquee anti-bacterial Augmentin and Amoxil brand rights in the U.S. to India's Dr. Reddy's Labs for an undisclosed sum
You may also be interested in...
MUMBAI - "It's my life and we will never sell Dr. Reddy's to an MNC," Kallam Anji Reddy, who founded the nearly $2 billion Indian company 25 years ago, told a television news channel in an interview to quell widespread speculation that the firm is the target of multinational companies for a potential acquisition
MUMBAI - Expanding its reach further into emerging markets for generic drugs, GlaxoSmithKline said it has reached an agreement with Dr. Reddy's Labs to develop and market select products across an extensive number of countries, except India
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).